The Ploegh Lab studies the various tactics that viruses employ to evade our immune responses, and the ways in which our immune system - both innate and adaptive - distinguishes friend from foe. The findings have illuminated not only host-pathogen interactions, but also aspects of protein quality control, an area to which the lab continues to apply chemistry-based strategies. Other technologies include new methods for protein labeling and the application of single domain antibody fragments, derived from camelid heavy chain only antibodies, for the purpose of non-invasive imaging of immune responses by positron emission tomography (immuno-PET) . Such single domain antibody fragments are being applied also for a variety of other purposes, including the disruption of the virus life cycle by intracellular expression of appropriately specific antibody fragments, opening up the possibility of phenotypic screens more generally.
Ploegh and his laboratory reported new mechanisms by which dendritic cells sense the presence of antigens and instruct the immune response, using Class II MHC-eGFP knockin mice and live cell imaging. In addition, Ploegh has helped elucidate how products of the major histocompatibility complex (MHC) are assembled and are delivered to the right destination to help an immune response kick in. Herpesviruses such as HCMV evade the immune system by selective destruction of Class I MHC products. A recent innovation is the generation of cloned mice with lymphocytes specific for pathogens such as Toxoplasma and herpesviruses, using the technique of somatic cell nuclear transfer.
Ploegh and his coworkers have emphasized the generation of the chemical tools with which to probe the ubiquitin-proteasome system. These tools include bacterially derived transacylases (sortases) as convenient tools for protein modification. A contributor to over 500 papers, Ploegh taught at Harvard Medical School where he headed the school’s immunology program (1997-2005). Prior to that, Ploegh was a Professor of Biology at MIT, working in the Center for Cancer Research (now David H. Koch Institute for Integrative Cancer Research).
About Hidde Ploegh
Dr. Ploegh received his Ph.D. from Leiden University in the Netherlands. A contributor to over 500 papers, Dr. Ploegh taught at Harvard Medical School where he headed the school’s immunology program (1997-2005). Prior to that, Ploegh was a Professor of Biology at MIT, working in the Center for Cancer Research (now David H. Koch Institute for Integrative Cancer Research).
Dr. Ploegh has been elected to the U.S. National Academy of Sciences, the American Academy of Arts and Sciences, and the European Molecular Biology Organization. He has received the Annual Prize from the Dutch Society for Biochemistry (1984), the National Institutes of Health Merit Award (1997), the Avery-Landsteiner Prize (2000), the Havinga Medal from Leiden University (2004), the Interbrew-Baillet Latour Health Prize (2006), the Meritorious Career Award from the American Association of Immunologists (AAI, 2011), and the National Institutes of Health Director's Pioneer Award (2012).